Bayer, Evotec Ink Agreement to Develop PCOS Treatments

Data : 09/01/2020 @ 08:16
Fonte : Dow Jones News
Titolo : Bayer AG (BAYN)
Quotazione : 71.26  -2.83 (-3.82%) @ 10:13
Quotazione Bayer Grafico

Bayer, Evotec Ink Agreement to Develop PCOS Treatments

Grafico Azioni Bayer (XE:BAYN)
Storico

2 Mesi : Da Dic 2019 a Feb 2020

Clicca qui per i Grafici di Bayer
   By Carlo Martuscelli 
 

Bayer AG (BAYN.XE) said Thursday that it will partner with Evotec SE (EVT.XE) to develop therapies for polycystic ovary syndrome, a common hormone disorder that affects women.

Under the terms of the five-year collaboration agreement, German drug discovery company Evotec is eligible for 16.5 million euros ($18.4 million) in research payments as well as more than EUR330 million in milestone payments, plus royalties generated from sales of treatments that enter the market.

Bayer and Evotec will collaborate in the early development stage, while Bayer will be responsible for clinical trials and commercialization, it said.

The two companies have previously signed collaboration deals to develop drugs targeting endometriosis and kidney disease.

 

Write to Carlo Martuscelli at carlo.martuscelli@wsj.com; @carlomartu

 

(END) Dow Jones Newswires

January 09, 2020 02:01 ET (07:01 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
La tua Cronologia
BIT
BMPS
Monte Pasc..
BITI
FTSEMIB
FTSE Mib
BIT
UCG
Unicredit
NASDAQ
AAPL
Apple
FX
EURUSD
Euro vs Do..
Le azioni che visualizzerai appariranno in questo riquadro, così potrai facilmente tornare alle quotazioni di tuo interesse.

Registrati ora per creare la tua watchlist personalizzata in tempo reale streaming.

Per accedere al tempo reale push di Borsa è necessario registrarsi.

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

P: V:it D:20200224 09:28:48